What is Wright Medical Group Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Wright Medical Group's annualized net income for the quarter that ended in Jun. 2015 was €-157.9 Mil. Wright Medical Group's average shareholder tangible equity for the quarter that ended in Jun. 2015 was €-18.1 Mil. Therefore, Wright Medical Group's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2015 was N/A%.
The historical rank and industry rank for Wright Medical Group's Return-on-Tangible-Equity or its related term are showing as below:
FRA:WM3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -556.64 Med: 1.09 Max: 8.55
Current: -556.64
During the past 13 years, Wright Medical Group's highest Return-on-Tangible-Equity was 8.55%. The lowest was -556.64%. And the median was 1.09%.
FRA:WM3's Return-on-Tangible-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.87
vs FRA:WM3: -556.64
Wright Medical Group Return-on-Tangible-Equity Historical Data
The historical data trend for Wright Medical Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Wright Medical Group Return-on-Tangible-Equity Chart
Competitive Comparison of Wright Medical Group's Return-on-Tangible-Equity
For the Medical Devices subindustry, Wright Medical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wright Medical Group's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Wright Medical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Wright Medical Group's Return-on-Tangible-Equity falls into.
Wright Medical Group Return-on-Tangible-Equity Calculation
Wright Medical Group's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2015) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Wright Medical Group (FRA:WM3) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Wright Medical Group Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Wright Medical Group's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Wright Medical Group (FRA:WM3) Business Description
Wright Medical Group Inc, through Wright Medical Technology, Inc. and other operating subsidiaries, is a specialty orthopaedic company, that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The Company provides surgical solutions for the foot and ankle market and markets its products in over 60 countries. Its business includes products that are used in foot and ankle repair, upper extremity products, and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow and shoulder, which it generally refer to as either foot and ankle or upper extremity products. The Company's manufacturing and warehousing operations are located in Arlington, Tennessee. Outside the U.S., The Company has distribution and administrative facilities in Amsterdam, the Netherlands, and sales and distribution offices in Canada, Australia, and Europe. The Company operates its continuing operations as one reportable segment and offer products in extremity reconstruction and biologics. The Company's products include CHARLOTTE, CLAW II, DARCO, EVOLVE, MICRONAIL, GRAFTJACKET, OSTEOSET. Its competitors include major companies in the orthopaedic and biologics industries, as well as academic institutions and other public and private research organizations that continue to conduct research, seek patent protection and establish arrangements for commercializing products. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act. Some of its products are also regulated by state agencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:WM3 has been successfully added to your 